Endocrine Abstracts

Objective: Radiotherapy (RT) can achieve tumour control rates of over 90% in pituitary adenomas. The commonest toxicity of irradiation is hypopituitarism. The exact incidence is variable and requires long-term testing for deficiency of all hypothalamic-pituitary axes (HPA). The aim of this study is to determine the time to onset of individual hormonal deficiencies and establish a timeframe for endocrine testing post-RT.Methods: We retrospectively assesse...

Introduction: PATRO Adults is an ongoing, longitudinal, noninterventional study assessing the long-term safety and efficacy of Omnitrope® (Sandoz; recombinant human growth hormone [rhGH]), among adults with severe growth hormone deficiency (GHD) treated in routine clinical practice in European countries. Omnitrope® was approved by the European Medicines Agency (EMA) in 2006, representing the first biosimilar approved by the EMA. We report the la...

Introduction: The daily maintenance dose of conventional hydrocortisone currently recommended by international guidelines for the management of primary adrenal insufficiency (PAI) or secondary adrenal insufficiency (SAI) is 15−25 mg/day, in 2−3 divided doses. The aim of this analysis was to investigate inter-country differences in glucocorticoid replacement doses in patients with PAI and SAI.Design: EU-AIR (ClinicalTrials.gov identifier: NCT0...

Introduction: If untreated, adrenal insufficiency (AI) leads to premature death. Hospital record data suggest mortality associated with primary (PAI) and secondary AI (SAI) to be 2–3-fold higher than in the general population. Major causes of death include cardiovascular disease, Addisonian crises, brain tumours and infections; however, there is little further characterization of patients who died.Design: We analysed real-world data from the Europea...

Introduction: Adrenal crises (ACs) are life-threatening events in patients with primary (PAI) or secondary (SAI) adrenal insufficiency, occurring ~4–10 times per 100 patient-years. Major causes of ACs are infections, especially gastroenteritis and tonsillitis/laryngitis. Risk factors for ACs remain ill defined, but could include concomitant endocrine diseases (diabetes mellitus, premature ovarian failure) in PAI, diabetes insipidus in SAI, and concomitant non-endocrine di...

Introduction: The ongoing, international, open, longitudinal, non-interventional study, PATRO Adults, aims to determine the long-term safety and efficacy of Omnitrope® (Sandoz), a recombinant human growth hormone (rhGH). Safety data from an interim analysis are presented here.Methods: Eligible patients are male or female adults who are receiving treatment with Omnitrope® and who have provided informed consent. Patients tre...

Background: Diabetes mellitus (DM) affects nearly is reported to be present in approximately 8% of cases of elective hip arthroplasty and an HBA1c >53 mmol/mol may be associated with poorer outcomes in these cases.Aims: To understand the demographics of DM patients in Glasgow undergoing elective hip arthroplasty over a 6 year period between Jan 2009 and Dec 2015 and the rate of post-operative complications.Methods: Patients wer...

Introduction: Long-term survivors of childhood-onset brain tumours have increased risk of premature vascular disease by mechanisms that remain unclear. We hypothesised that a thrombotic fibrin network profile is one mechanism for the increased vascular risk in this population.Methods: We undertook a cross-sectional study in 33 patients with previous history of brain tumours and 33 age and sex-matched healthy controls. We performed clot structure analysis...

Background: Diagnosing secondary hypothyroidism can be challenging, particularly for patients with low-normal free T4 (fT4). Thyroid hormone replacement (THR) in these cases is guided by the normal population fT4 range. The aim of this study was to compare thyroid function tests in thyroid cancer patients on THR and patients with pituitary diseases with or without central hypothyroidism.Methods: We retrospectively collect...

Introduction: Prednisolone is the standard treatment for most inflammatory conditions. However, it is also used in hormone replacement therapy in adrenal insufficiency (AI) for historical reasons or due to its longer half-life and once-daily application. Recent data indicate that daily prednisolone could be associated with lower bone mineral density than daily hydrocortisone in patients with AI. However, data on risk factors for cardiovascular disease in patients with AI treat...